Watchlist Price Alert

Quest Diagnostics (DGX)

NYSE: DGX · Real-Time Price · USD

177.53

-0.42 (-0.24%)

At close: May 05, 2025, 3:59 PM

177.57

0.02%

After-hours: May 05, 2025, 07:35 PM EDT

-0.24% (1D)

Bid	176.87
Market Cap	19.82B
Revenue (ttm)	10.16B
Net Income (ttm)	897M
EPS (ttm)	7.68
PE Ratio (ttm)	23.12
Forward PE	16.85
Analyst	Hold

Ask	180
Volume	680,418
Avg. Volume (20D)	1,408,324.7
Open	177.12
Previous Close	177.95
Day's Range	177.12 - 179.28
52-Week Range	135.35 - 179.32
Beta	0.78

About DGX

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPat...

Sector Healthcare

IPO Date Dec 17, 1996

Employees 55,000

Stock Exchange NYSE

Ticker Symbol DGX

Website https://www.questdiagnostics.com

Full Company Profile

Analyst Forecast

According to 14 analyst ratings, the average rating for DGX stock is "Hold." The 12-month stock price forecast is $185, which is an increase of 4.21% from the latest price.

Stock Forecasts

Why Price Moved

1 week ago

+6.78%

Quest Diagnostics shares are trading higher follow... Unlock content with Pro Subscription

1 month ago

-2.57%

Quest Diagnostics shares are trading lower after the company issued Q1 revenue and EPS guidance below estimates.

News

17 hours ago · zacks.com

Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

2 days ago · seekingalpha.com

Quest Diagnostics: A Leader But Waiting For Better Price

Quest Diagnostics excels in scale, scope, and service quality, leveraging automation and distribution to reduce costs and offer comprehensive test menus. Despite its strengths, I recommend waiting to ...

1 week ago · benzinga.com

These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings

Quest Diagnostics Incorporated DGX posted better-than-expected first-quarter earnings on Tuesday.

2 weeks ago · benzinga.com

Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence

Quest Diagnostics Inc DGX reported on Tuesday that first-quarter 2025 sales of $2.65 billion, up 12.1% year over year, beat the consensus of $2.63 billion.

2 weeks ago · seekingalpha.com

Quest Diagnostics Incorporated (DGX) Q1 2025 Earnings Call Transcript

Quest Diagnostics Incorporated (NYSE:DGX ) Q1 2025 Results Conference Call April 22, 2025 8:30 AM ET Company Participants Shawn Bevec - Vice President of Investor Relations Jim Davis - Chairman, Chief...

2 weeks ago · zacks.com

Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up

DGX delivers solid top-line growth in the first quarter of 2025.

1 week ago · zacks.com

Quest Diagnostics (DGX) Q1 Earnings and Revenues Beat Estimates

Quest Diagnostics (DGX) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.04 per share a year ago.

1 week ago · reuters.com

Quest beats quarterly profit estimates on strong demand for diagnostic tests

Laboratory operator Quest Diagnostics beat Wall Street estimates for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests.

1 week ago · marketwatch.com

Quest Diagnostics earnings beat after March rebound in demand from slump early in the quarter

Quest Diagnostics Inc.'s stock fell 3.6% early Tuesday, after the company posted better-than-expected first-quarter earnings and backed its guidance, but said the early part of the quarter was slow.

3 weeks ago · zacks.com

Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy?

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Load More News